MegaRobo Technologies, a Chinese start-up that uses artificial intelligence and robotics in life sciences research, has raised $300 million in a funding round led by Goldman Sachs Asset Management, Asia Investment Capital and GGV Capital.
The six-year-old company is the latest start-up from the pharmaceutical industry to capitalize on a jump in investor interest in the sector after the COVID-19 pandemic.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Market research platform AlphaSense also raised $225 million on Wednesday in a funding round that valued it at $1.7 billion, while biotechnology firm Synthego earlier this year raised $200 million in a fundraise led by hedge fund Perceptive Advisors, with participation from SoftBank Vision Fund 2.
Source: Reuters
Can’t stop reading? Read more
AURELIUS exits LSG Asia-Pacific after operational turnaround and margin expansion
AURELIUS exits LSG Asia-Pacific after operational turnaround and margin expansion AURELIUS has...
Ares lands $9.8bn for flagship opportunistic credit strategy
Ares lands $9.8bn for flagship opportunistic credit strategy Ares has raised more than $9.8bn for...
CVC DIF appoints Enrico Del Prete to scale $25bn value-add platform
CVC DIF appoints Enrico Del Prete to scale $25bn value-add platform CVC DIF has appointed Enrico...